You are here

SBIR Phase I: Development of an oral recombinant subunit vaccine to protect against COVID-19

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2031281
Agency Tracking Number: 2031281
Amount: $256,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: PT
Solicitation Number: N/A
Timeline
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-01
Award End Date (Contract End Date): 2021-08-31
Small Business Information
2213 EVENING SUN RD
NAZARETH, PA 18064
United States
DUNS: 962757584
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Elodie Burlet
 (610) 849-5054
 elodie.burlet@vaxform.com
Business Contact
 Elodie Burlet
Phone: (610) 849-5054
Email: elodie.burlet@vaxform.com
Research Institution
N/A
Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a new self-administered vaccine for COVID-19 using a novel oral delivery platform. This project will develop a new technique to genera

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government